What is Enterin?
Enterin, Inc. is a research-focused entity dedicated to addressing the challenges posed by neurodegenerative diseases, with a particular emphasis on Parkinson's disease. The company leverages its findings and insights to improve patient outcomes, targeting both individuals suffering from Parkinson's and healthcare professionals seeking advanced therapeutic solutions. Enterin's commitment lies in advancing the understanding and treatment of these debilitating conditions through scientific innovation.
How much funding has Enterin raised?
Enterin has raised a total of $13.1M across 3 funding rounds:
Series A
$12.7M
Debt
$150K
Debt
$293K
Series A (2017): $12.7M with participation from New Ventures III
Debt (2020): $150K led by PPP
Debt (2021): $293K supported by PPP
Key Investors in Enterin
New Ventures III
New Ventures III is a venture capital firm specializing in investments across the healthcare industry, from early-stage startups to established drug development companies. Based in Virginia Beach, Virginia, they focus on identifying and supporting innovative healthcare solutions.
PPP
Public-Private Partnership
PPP
Public-Private Partnership
What's next for Enterin?
With a substantial enterprise-level funding context, Enterin, Inc. is positioned for significant advancements in its Parkinson's research initiatives. The recent strategic investment signals confidence from backers in the company's potential to develop novel treatments and diagnostic tools. This capital infusion is expected to accelerate research and development pipelines, potentially leading to clinical trials and the eventual commercialization of therapies aimed at improving the quality of life for patients affected by neurodegenerative disorders. The company's trajectory suggests a focus on scaling its research capabilities and forging strategic partnerships within the healthcare and biotechnology sectors.
See full Enterin company page
